Merck sought to reformulate Vioxx in 2000
Key points
- Inc. researchers sought to reformulate the arthritis drug Vioxx five years ago to reduce its cardiovascular side effects, even as the company publicly played down data showing potential Heart attack risk, according to a report released early by The New England Journal of Medicine.
- A study in March 2000 found that patients taking Vioxx were five times more likely to have Heart attacks than individuals using the generic medicine naproxen.
- The New England Journal of Medicine, citing an internal document, reported that company scientists were privately considering combining Vioxx with another agent to reduce the risk of Heart attacks and Strokes.
- The document, a communication between Merck researchers and the company's patent department, stated that the way Vioxx works to reduce pain might also increase cardiovascular problems.
Merck & Co. Inc. researchers sought to reformulate the arthritis drug Vioxx five years ago to reduce its cardiovascular side effects, even as the company publicly played down data showing potential Heart attack risk, according to a report released early by The New England Journal of Medicine.
A study in March 2000 found that patients taking Vioxx were five times more likely to have Heart attacks than individuals using the generic medicine naproxen. Merck maintained at the time that this was a result of naproxen's cardioprotective properties and not any defect in Vioxx.
The New England Journal of Medicine, citing an internal document, reported that company scientists were privately considering combining Vioxx with another agent to reduce the risk of Heart attacks and Strokes.
The document, a communication between Merck researchers and the company's patent department, stated that the way Vioxx works to reduce pain might also increase cardiovascular problems. The researchers suggested a patent be sought for a combination drug mixing Vioxx with another agent to lessen the risk, according to the AP report.
A spokesman for Merck was not immediately available to comment. The AP report quoted a Merck official as saying the company believes it acted responsibly.
Merck pulled Vioxx off the market last fall after a study showed it doubled the risk of heart attack and stroke in patients taking the drug for more than 18 months.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Addiction →
NewsExperts raise questions about Vioxx decision
Two leading heart experts called for urgent investigations on Wednesday into whether all painkilling drugs known as COX-2 inhibitors may raise the risk of heart attack in some people. They also called for a…
8 October 2004
NewsVioxx study finds arthritis drug increases heart attack risk
An FDA financed study presented at an epidemiologists conference in Bordeaux, France on August 25, 2004 suggested Vioxx patients have a 50 percent greater chance of suffering heart attacks and sudden cardiac death than…
3 September 2004
NewsBaby aspirin plus Vioxx raises ulcer risk
By themselves, low-dose aspirin and the painkiller Vioxx are usually safe for the stomach, but together they can spell trouble, a new study indicates. The findings may be relevant to many people who take aspirin to…